Table 5.
Number of bleeding events per study participant during the 12-month on-demand and prophylactic treatment periods
| On-demand therapy (arm 2) | Prophylactic therapy (arm 3) | |||||||||
| Study participant (sex, age, VWD type) | Months 1–3 | Months 4–6 | Months 7–9 | Months 10–12 | Total | Months 1–3 | Months 4–6 | Months 7–9 | Months 10–12 | Total |
| All study participants | 75 | 61 | 75 | 93 | 304 | 2 | 2 | 1 | 5 | 10 |
| (Male, 54 years, type 3) | 16 | 19 | 20 | 15 | 70 | 0 | 0 | 0 | 1 | 1 |
| (Male, 68 years, type 3) | 20 | 12 | 19 | 31 | 82 | 1 | 0 | 1 | 4 | 6 |
| (Male, 55 years, type 3) | 7 | 3 | 5 | 7 | 22 | 0 | 1 | 0 | 0 | 1 |
| (Female, 37 years, type 3) | 7 | 5 | 4 | 4 | 20 | 0 | 0 | 0 | 0 | 0 |
| (Male, 28 years, type 3) | 9 | 6 | 7 | 9 | 31 | 0 | 1 | 0 | 0 | 1 |
| (Male, 33 years, type 2A) | 7 | 9 | 10 | 15 | 41 | 0 | 0 | 0 | 0 | 0 |
| (Female, 48 years, type 1) | 5 | 3 | 5 | 5 | 18 | 1 | 0 | 0 | 0 | 1 |
| (Male, 21 years, type 3) | 4 | 4 | 5 | 7 | 20 | 0 | 0 | 0 | 0 | 0 |
VWD, von Willebrand disease.